Latest Kaposi's sarcoma-associated herpesvirus Stories
First treatment approved for patients with rare blood disorder HORSHAM, Pa., April 23, 2014 /PRNewswire/ -- Janssen Biotech, Inc. ["Janssen"] today announced the U.S.
New research from the Trudeau Institute addresses how the human body controls gamma-herpesviruses, a class of viruses thought to cause a variety of cancers.
Research from the University of Leeds has identified how the virus which causes Kaposi's Sarcoma replicates and spreads â€“ opening a door to a possible new treatment for the disease.
UCSF researchers have identified a new potential drug target for the herpes virus that causes Kaposiâ€™s sarcoma, re-opening the possibility of using the class of drugs called protease inhibitors against the full herpes family of viruses, which for 20 years has been deemed too difficult to attain.
Scientists know that some cancers are triggered by viruses, which take over cellular systems and cause uncontrolled cell growth. Doctors â€“ and patients who get shingles late in life â€“ have also known for many years that some viruses, particularly the herpes virus, can lie dormant in a person's cells for long periods of time and then reactivate, causing disease.
Kaposi's sarcoma-associated herpesvirus (KSHV) one of seven currently known human cancer virus, is also the eighth human herpesvirus. Kaposi's sarcoma, caused by the virus, is common in AIDS patients, primary effusion lymphoma, and some types of multicentric Castelman's disease. Moritz Kaposi discovered the blood vessel tumor, in 1872, which would eventually be names Kaposi's sarcoma. It was originally though that KS was of Jewish and Mediterranean origins until it was found to be common...